Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Leukemia, Myeloid, Acute 6Myelodysplastic Syndromes 4Primary Myelofibrosis 2Myeloproliferative Disorders 2Thrombocythemia, Essential 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Recurrence 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Neoplasms, Germ Cell and Embryonal 1Neoplasm Metastasis 1Melanoma 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia 1Carcinoma, Squamous Cell 1

Interventions

Docetaxel 11Prednisone 10Leuprolide 10Magnetic Resonance Spectroscopy 9bicalutamide 8Radiotherapy 7Abiraterone Acetate 7Biopsy 6gallium 68 PSMA-11 5acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 5Surveys and Questionnaires 5Metformin 5Goserelin 5radium Ra 223 dichloride 4enzalutamide 4apalutamide 4Specimen Handling 4Injections 4Androgen Antagonists 4pembrolizumab 3orteronel 3cabazitaxel 3abiraterone 3Radiotherapy, Intensity-Modulated 3Radiosurgery 3Pioglitazone 3Paclitaxel 3Exercise 3Brachytherapy 3Blood Specimen Collection 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Prostatic Neoplasms × Decitabine × Clear all
NCT03709550 2022-10-05

Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer

Roswell Park Cancer Institute

Phase 1/2 Withdrawn
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡